Filing Flows › Vistagen Therapeutics (VTGN) › Q1 FY27 › vs Q1 FY26
Vistagen Therapeutics (VTGN) Q1 FY27 vs Q1 FY26 (year over year)
Vistagen Therapeutics's revenue rose $1.2M (+505%) from $244K in Q1 FY26 to $1.5M in Q1 FY27.
Vistagen Therapeutics, Q1 FY27: revenue $1.5M (+505% year over year), operating margin -904.3%, net loss $13.0M, operating cash flow −$14.7M. The chart draws each line against Q1 FY26, the increases inside each band.
Every line
| Line | Q1 FY27 | Q1 FY26 | Change | % |
|---|---|---|---|---|
| Revenue | $1.5M | $244K | $1.2M | +505% |
| Other income, net | $318K | $709K | −$391K | -55% |
| Net loss | $13.0M | $15.1M | −$2.1M | -14% |
| Costs & expenses | $14.8M | $16.0M | −$1.2M | -8% |
| Operating costs | $14.8M | $16.0M | −$1.2M | -8% |
| Research & development | $10.9M | $11.7M | −$772K | -7% |
| General & admin | $3.9M | $4.4M | −$452K | -10% |
| Operating cash sources | $15.8M | $19.8M | −$4.1M | -20% |
| Depreciation & amortization | $52K | $40K | $12K | +30% |
| Share-based compensation | $991K | $916K | $75K | +8% |
| Cash used in operations | $14.7M | $18.8M | −$4.1M | -22% |
| Net loss absorbed | $13.0M | $15.1M | −$2.1M | -14% |
| Working capital & other | $2.7M | $4.7M | −$2.0M | -42% |
Questions
How much did Vistagen Therapeutics's revenue grow year over year in Q1 FY27?
Vistagen Therapeutics's revenue rose $1.2M (+505%) from $244K in Q1 FY26 to $1.5M in Q1 FY27.